Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD – Celgene
03. Consultee comments on the ACD – MDS UK
04. Consultee comments on the ACD – Royal College of Physicians
05. Consultee comments on the ACD – Royal College of Pathologists
06. Patient expert comments on the ACD – Pirilla
07. Evidence Review Group addendum – Kleijnen Reviews
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
24 October 2013 (2.62 Mb 13 mins ) |
This page was last updated: 18 October 2013